584 related articles for article (PubMed ID: 21149776)
1. Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection.
Ishibashi S; Tawara A; Sohma R; Kubota T; Toh N
Arch Ophthalmol; 2010 Dec; 128(12):1539-45. PubMed ID: 21149776
[TBL] [Abstract][Full Text] [Related]
2. [Effect of Intravitreal Bevacizumab Injection on Iris and Iridocorneal Angle Neovascularization in Neovascular Glaucoma].
Ishibashi S; Kondo H
J UOEH; 2015 Dec; 37(4):299-304. PubMed ID: 26667197
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
5. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma.
Batioğlu F; Astam N; Ozmert E
Int Ophthalmol; 2008 Feb; 28(1):59-61. PubMed ID: 17609852
[TBL] [Abstract][Full Text] [Related]
6. Intracameral bevacizumab for iris rubeosis.
Grisanti S; Biester S; Peters S; Tatar O; Ziemssen F; Bartz-Schmidt KU;
Am J Ophthalmol; 2006 Jul; 142(1):158-60. PubMed ID: 16815268
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series.
Kotecha A; Spratt A; Ogunbowale L; dell'Omo R; Kulkarni A; Bunce C; Franks WA
Arch Ophthalmol; 2011 Feb; 129(2):145-50. PubMed ID: 21320957
[TBL] [Abstract][Full Text] [Related]
8. In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with Ahmed valve implantation.
Shin JP; Lee JW; Sohn BJ; Kim HK; Kim SY
J Glaucoma; 2009; 18(8):589-94. PubMed ID: 19826387
[TBL] [Abstract][Full Text] [Related]
9. Regression of neovascular iris vessels by intravitreal injection of bevacizumab.
Mason JO; Albert MA; Mays A; Vail R
Retina; 2006 Sep; 26(7):839-41. PubMed ID: 16963866
[No Abstract] [Full Text] [Related]
10. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C.
Alkawas AA; Shahien EA; Hussein AM
J Glaucoma; 2010 Dec; 19(9):622-6. PubMed ID: 20179624
[TBL] [Abstract][Full Text] [Related]
11. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma.
Chalam KV; Gupta SK; Grover S; Brar VS; Agarwal S
Eur J Ophthalmol; 2008; 18(2):255-62. PubMed ID: 18320519
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab.
Lupinacci AP; Calzada JI; Rafieetery M; Charles S; Netland PA
Adv Ther; 2009 Feb; 26(2):208-16. PubMed ID: 19234680
[TBL] [Abstract][Full Text] [Related]
13. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma.
Silva Paula J; Jorge R; Alves Costa R; Rodrigues Mde L; Scott IU
Acta Ophthalmol Scand; 2006 Aug; 84(4):556-7. PubMed ID: 16879583
[No Abstract] [Full Text] [Related]
14. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
[TBL] [Abstract][Full Text] [Related]
15. [Intravitreal bevacizumab in the treatment of neovascular glaucoma].
Ouhadj O; Chergui I; Mendil L; Nouri MT
J Fr Ophtalmol; 2009 Feb; 32(2):112-6. PubMed ID: 20579473
[TBL] [Abstract][Full Text] [Related]
16. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients.
Duch S; Buchacra O; Milla E; Andreu D; Tellez J
J Glaucoma; 2009 Feb; 18(2):140-3. PubMed ID: 19225351
[TBL] [Abstract][Full Text] [Related]
17. Effect of intravitreal injection of high-dose bevacizumab in monkey eyes.
Sakurai K; Akiyama H; Shimoda Y; Yoshida I; Kurabayashi M; Kishi S
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4905-16. PubMed ID: 19407010
[TBL] [Abstract][Full Text] [Related]
18. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.
Hatta Y; Ishikawa K; Nishihara H; Ozawa S; Ito Y; Terasaki H
Retina; 2010 Mar; 30(3):495-502. PubMed ID: 19996828
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal triamcinolone after intravitreal bevacizumab for retinal vein occlusions.
Jonas JB; Libondi T; Schlichtenbrede F; Schmidbauer M
Acta Ophthalmol; 2010 Mar; 88(2):e24-5. PubMed ID: 19493250
[No Abstract] [Full Text] [Related]
20. Clinical and histological findings after intravitreal injection of bevacizumab (Avastin) in a porcine model of choroidal neovascularization.
Lassota N; Prause JU; Scherfig E; Kiilgaard JF; la Cour M
Acta Ophthalmol; 2010 May; 88(3):300-8. PubMed ID: 19416113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
